title: Is radioembolization or sorafenib the best option for patients with hepatocellular carcinoma and portal vein invasion?
authors.affiliation: Department of Oncology Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: Ying-Yang
authors.initials: YY
authors.lastname: Liao
authors.affiliation: Department of Oncology Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: Jian-Hong
authors.initials: JH
authors.lastname: Zhong
authors.affiliation: Department of Oncology Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: Ning-Fu
authors.initials: NF
authors.lastname: Peng
authors.affiliation: Department of Oncology Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: Le-Qun
authors.initials: LQ
authors.lastname: Li
authors.affiliation: Department of Mathematics, Hong Kong Baptist University, Hong Kong, Hong Kong.
authors.forename: Tie-Jun
authors.initials: TJ
authors.lastname: Tong
mesh_terms: D006528:Carcinoma, Hepatocellular; D006801:Humans; D008113:Liver Neoplasms; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011169:Portal Vein; D000077157:Sorafenib
chemical_list: D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib